The Department of Pathology and Laboratory Medicine, in conjunction with the Abramson Cancer Center, is at the leading edge of personalized medicine with its Center for Personalized Diagnostics and the Clinical Cell and Vaccine Production Facility. To learn more about the Center for Personalized Diagnostics, visit http://www.pennmedicine.org/personalized-diagnostics/.
Penn Medicine's Department of Pathology and Laboratory Medicine is at the forefront of shaping the future of personalized medicine and, in conjunction with the Abramson Cancer Center, is developing a Center for Personalized Diagnostics, integrating molecular pathology, pathology informatics, and genomic pathology for diagnosis and research. The Department also maintains the Clinical Cell and Vaccine Production Facility as an ACC Shared Resource.
A key component in personalized medicine is diagnostics: the ability to identify molecular signatures present, for example, in the DNA of tumor cells. Collection of a large number of molecular
PENN MEDICINES CANCER VACCINE: The Future of Cancer Treatment About this Event: Dr. Janos Tanyi from the University of Pennsylvania Abramsons Cancer Center Will Explain How a Vaccine Made from a Patients Own Tumor Boosts the Immune System to Kill Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. On Thursday, December 5th at 6:30 pm Dr. Janos Tanyi, MD, PhD, Surgeon and Assistant Professor of Obstetrics and Gynecology at the University of Pennsylvania Abramsons Cancer Centers Perelman Center for Advanced Medicine and Principal Investigator will be at Gildas Club Delaware Valley. Dr. Tanyi will explain to cancer patients and survivors as well as health care practitioners how Penn Medicines two-step personalized immunotherapy treatment works. In the first step, the cancer patients own dendritic cells and tumor cells are used to generate a personalized vaccine that can kill the patient's own tumor. In step two, the patients T-cells trigger an anti-tumor immune response that kills cancer cells. The trial vaccine studys lead author, Lana Kandalaft, PharmD, PhD, MTR,
Katrina Armstrong, MD, MSCE, Director of General Internal Medicine and Associate Director at Abramson Cancer Center discusses recent controversy regarding US Preventive Services Task Force Breast Cancer Screening Guidelines.
Carrie Stricker, PhD, RN, AOCN - Treatment Summaries Oncology Nurse Practitioner, Abramson Cancer Center Clinical Assistant Professor, School of Nursing, Abramson Cancer Center, University of Pennsylvania
What would you give for more time with your family your friends your dreams? What would you do to stop the anxiety the fear to stop your cancer from spreading. Is your life worth another treatment a new therapy a different outcome altogether? The answer is the Abramson Cancer Center at Penn.
With more breakthrough treatments than anywhere else in the region: Like a vaccine that can fight cancer. A proton beam that destroys tumors with precision. And specialists with the experience to treat cancer at every stage Penn's Abramson Cancer Center has more ways to save your life.
When faced with cancer. When you need a reason to hope. When the only option is every option. Your life is worth Penn Medicine. To learn more visit http://www.PennMedicine.org or call 800-789-PENN.
On December 2nd, 2013, almost 400 people came together to celebrate the Abramson Cancer Center's (ACC) 40th Anniversary of being designated a Comprehensive Cancer Center by the National Cancer Institute. This momentous milestone granted us the opportunity to celebrate achievements in cancer research, patient care, and education during the last four decades that bring hope to patients and their families affected by cancer. Tara shared her story